Education
About Us
Working with TipRanks
Follow Us
Eloxx Pharmaceuticals (ELOX)
:ELOX
ELOX Stock Chart & Stats
$0.75
$0.00(0.00%)
At close: 4:00 PM EST
$0.75
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.02 - $0.75
Previous CloseN/A
Volume500.00
Average Volume (3M)32.00
Market Cap
$330.00
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-1765.26
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.06
Shares Outstanding3,300,528
10 Day Avg. Volume32
30 Day Avg. Volume32
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Eloxx Pharmaceuticals News
ELOX FAQ
What was Eloxx Pharmaceuticals’s price range in the past 12 months?
Eloxx Pharmaceuticals lowest stock price was $0.02 and its highest was $0.75 in the past 12 months.
What is Eloxx Pharmaceuticals’s market cap?
Eloxx Pharmaceuticals’s market cap is $330.00.
When is Eloxx Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Eloxx Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Eloxx Pharmaceuticals overvalued?
According to Wall Street analysts Eloxx Pharmaceuticals’s price is currently Overvalued.
Does Eloxx Pharmaceuticals pay dividends?
Eloxx Pharmaceuticals does not currently pay dividends.
What is Eloxx Pharmaceuticals’s EPS estimate?
Eloxx Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eloxx Pharmaceuticals have?
Eloxx Pharmaceuticals has 3,300,528 shares outstanding.
What happened to Eloxx Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Eloxx Pharmaceuticals?
Currently, no hedge funds are holding shares in ELOX
Company Description
Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
Biodexa Pharmaceuticals
―
Salarius Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―
Onconetix
―
Ownership Overview
7.89% Insiders
<0.01% Other Institutional Investors
92.10% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---